Información del artículo
El Texto completo está disponible en PDF
Blbliografía
[1.]
F. Davidoff, J.M. Drazen, J. Hoey, L. Højgaard, R. Horton, S. Kotzin, et al.
Sponsorship, authorship, and accountability. Editorial.
N Engl J Med, 345 (2001), pp. 825-827
[2.]
L. Henderson, A.M.C. More.
Finding growth from reform.
Center Watch, 1 (2000), pp. 10-13
[3.]
Kowalczyk L. Harvard, other medical schools aim to give drug firms faster pace for trials. Boston Golbe, july 28, 2000; C4
[4.]
Parexel's pharmaceutical R&D statistical sourcebook, 1998,
[6.]
J.O. Kahn, D.W. Cherng, K. Mayer, H. Murray, S. Lagakos.
Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 106/L CD4 cell counts: A randomized controlled trial.
Jama, 284 (2000), pp. 2193-2202
Copyright © 2002. Asociación Española de Pediatría
